A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Primary Purpose
Advanced Solid Tumors
Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Debio 0123
Sponsored by

About this trial
This is an interventional treatment trial for Advanced Solid Tumors focused on measuring Advanced Solid Tumors, WEE1-inhibitor
Eligibility Criteria
Inclusion Criteria:
Part 1 dose escalation only
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors.
- Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
- Disease progression under or following standard therapy and/or no available standard therapy of proven benefit.
Part 2 expansion only
o Measurable disease per RECIST version 1.1 criteria
Part 1 dose escalation and Part 2 expansion
- Accessible tumor for biopsy, and participant willing to undergo tumor biopsy unless archived tumor sample is available.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) PS 0-1.
- Life expectancy of at least 3 months, in the best judgment of the Investigator.
- Adequate bone marrow, liver biochemistry, renal function, and coagulation status.
- Willing to practice highly effective methods of contraception.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
- Participants with active second malignancies requiring therapy in the last 6 months, with the exception of superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated surgically.
- Current use of an investigational agent or a medical device.
- Major surgery ≤4 weeks prior to the first dose of study treatment or who have not recovered from the surgical procedure.
- Brain tumors and/or brain metastases unless they are asymptomatic, stable on recent imaging (not dated more than 28 days from the inclusion date), and have not required active treatment in the last month before study entry.
- History of myocardial infarction or stroke within 6 months, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, family history of sudden death from cardiac-related causes, or any cardiotoxicity experienced after previous chemotherapy.
- Known infection requiring systemic use of an antibiotic or antiviral agent.
- Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccines.
- Pregnancy or breast-feeding.
- Inability or unwillingness to swallow oral medication.
- Clinically significant gastrointestinal abnormality that would affect the absorption of the drug.
- Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to starting study treatment. Palliative radiation for pain relief is allowed up to 1 week prior to starting study treatment.
- Unresolved AEs or toxicities due to previous treatments, i.e., >Grade 1 or >Grade 2 for alopecia and endocrinopathies controlled by replacement therapy (example, hypothyroidism due to immune checkpoint inhibitors)
[Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.]
Sites / Locations
- South Texas Accelerated Research Therapeutics (START) MidwestRecruiting
- South Texas Accelerated Research Therapeutics (START)Recruiting
- Istituto Oncologico della Svizzera italiana - Ente Ospedaliero CantonaleRecruiting
- Universitätsspital Zürich, Dermatologische KlinikRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Part 1: Dose Escalation
Part 2: Expansion
Arm Description
Participants will receive Debio 0123 orally in escalating dose cohorts during each 21-day treatment cycle until progression of disease, unacceptable toxicity, participant's withdrawal, or Investigator's decision, whichever occurs first.
Debio 0123 at the RP2D established in Part 1.
Outcomes
Primary Outcome Measures
Part 1: Maximum Tolerated Dose (MTD) as Determined by Percentage of Participants with Dose Limiting Toxicities (DLTs)
Part 1: Recommended Phase 2 Dose (RP2D) as Determined by Percentage of Participants with DLTs and Cumulative Safety
Part 2: Percentage of Participants with Serious Adverse Events (SAEs)
Part 2: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) and Laboratory Abnormalities
Part 2: Percentage of Participants with Treatment Discontinuations and Treatment Modifications due to Adverse Events (AEs) and Laboratory Abnormalities
Part 2: Overall Response Rate (ORR)
Secondary Outcome Measures
Part 1: Percentage of Participants with SAEs
Part 1: Percentage of Participants with TEAEs and Laboratory Abnormalities
Part 1: Plasma Concentration of Debio 0123
The pharmacokinetics (PK) of Debio-0123 will be evaluated in plasma.
Parts 1 and 2: Anti-Tumor Activity as Assessed by Percentage of Participants with Tumor Response
Full Information
NCT ID
NCT05109975
First Posted
October 26, 2021
Last Updated
August 25, 2023
Sponsor
Debiopharm International SA
1. Study Identification
Unique Protocol Identification Number
NCT05109975
Brief Title
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Official Title
A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 5, 2021 (Actual)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Debiopharm International SA
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of Debio 0123 as monotherapy with repeated dosing in adults with advanced solid tumors that recurred or progressed after prior therapy and/or for whom no standard therapy of proven benefit is available.
The purpose in Part 2, Expansion Part of this study, is to characterize the safety and tolerability of Debio 0123 when administered as monotherapy at the MTD/RP2D determined during the Dose Escalation Part 1 and to evaluate the preliminary anti-tumor activity of Debio 0123 when administered as monotherapy in participants with specific solid tumor types that recurred or progressed following prior lines of therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumors
Keywords
Advanced Solid Tumors, WEE1-inhibitor
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
130 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Part 1: Dose Escalation
Arm Type
Experimental
Arm Description
Participants will receive Debio 0123 orally in escalating dose cohorts during each 21-day treatment cycle until progression of disease, unacceptable toxicity, participant's withdrawal, or Investigator's decision, whichever occurs first.
Arm Title
Part 2: Expansion
Arm Type
Experimental
Arm Description
Debio 0123 at the RP2D established in Part 1.
Intervention Type
Drug
Intervention Name(s)
Debio 0123
Intervention Description
Debio 0123 orally during 21-day treatment cycles.
Primary Outcome Measure Information:
Title
Part 1: Maximum Tolerated Dose (MTD) as Determined by Percentage of Participants with Dose Limiting Toxicities (DLTs)
Time Frame
Cycle 1 (each cycle is 21 days)
Title
Part 1: Recommended Phase 2 Dose (RP2D) as Determined by Percentage of Participants with DLTs and Cumulative Safety
Time Frame
Cycle 1 (each cycle is 21 days)
Title
Part 2: Percentage of Participants with Serious Adverse Events (SAEs)
Time Frame
Up to 30 days after the last dose of study treatment (up to 13 months)
Title
Part 2: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) and Laboratory Abnormalities
Time Frame
Up to 30 days after the last dose of study treatment (up to 13 months)
Title
Part 2: Percentage of Participants with Treatment Discontinuations and Treatment Modifications due to Adverse Events (AEs) and Laboratory Abnormalities
Time Frame
Up to end of study treatment (up to 12 months)
Title
Part 2: Overall Response Rate (ORR)
Time Frame
From the start of study treatment until disease progression (up to 12 months)
Secondary Outcome Measure Information:
Title
Part 1: Percentage of Participants with SAEs
Time Frame
Up to 30 days after the last dose of study treatment (up to 13 months)
Title
Part 1: Percentage of Participants with TEAEs and Laboratory Abnormalities
Time Frame
Up to 30 days after the last dose of study treatment (up to 13 months)
Title
Part 1: Plasma Concentration of Debio 0123
Description
The pharmacokinetics (PK) of Debio-0123 will be evaluated in plasma.
Time Frame
Pre-dose and at multiple time points up to 8 hours (h) on Day 1, Cycle 1 (each cycle is 21 days)
Title
Parts 1 and 2: Anti-Tumor Activity as Assessed by Percentage of Participants with Tumor Response
Time Frame
Parts 1 and 2: Up to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Part 1 dose escalation only
Histologically or cytologically confirmed locally advanced or metastatic solid tumors.
Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
Disease progression under or following standard therapy and/or no available standard therapy of proven benefit.
Part 2 expansion only
o Measurable disease per RECIST version 1.1 criteria
Part 1 dose escalation and Part 2 expansion
Accessible tumor for biopsy, and participant willing to undergo tumor biopsy unless archived tumor sample is available.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) PS 0-1.
Life expectancy of at least 3 months, in the best judgment of the Investigator.
Adequate bone marrow, liver biochemistry, renal function, and coagulation status.
Willing to practice highly effective methods of contraception.
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
Participants with active second malignancies requiring therapy in the last 6 months, with the exception of superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated surgically.
Current use of an investigational agent or a medical device.
Major surgery ≤4 weeks prior to the first dose of study treatment or who have not recovered from the surgical procedure.
Brain tumors and/or brain metastases unless they are asymptomatic, stable on recent imaging (not dated more than 28 days from the inclusion date), and have not required active treatment in the last month before study entry.
History of myocardial infarction or stroke within 6 months, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, family history of sudden death from cardiac-related causes, or any cardiotoxicity experienced after previous chemotherapy.
Known infection requiring systemic use of an antibiotic or antiviral agent.
Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccines.
Pregnancy or breast-feeding.
Inability or unwillingness to swallow oral medication.
Clinically significant gastrointestinal abnormality that would affect the absorption of the drug.
Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to starting study treatment. Palliative radiation for pain relief is allowed up to 1 week prior to starting study treatment.
Unresolved AEs or toxicities due to previous treatments, i.e., >Grade 1 or >Grade 2 for alopecia and endocrinopathies controlled by replacement therapy (example, hypothyroidism due to immune checkpoint inhibitors)
[Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.]
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Debiopharm International S.A
Phone
+41 21 321 01 11
Email
clinicaltrials@debiopharm.com
Facility Information:
Facility Name
South Texas Accelerated Research Therapeutics (START) Midwest
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49546
Country
United States
Individual Site Status
Recruiting
Facility Name
South Texas Accelerated Research Therapeutics (START)
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Name
Istituto Oncologico della Svizzera italiana - Ente Ospedaliero Cantonale
City
Bellinzona
ZIP/Postal Code
6500
Country
Switzerland
Individual Site Status
Recruiting
Facility Name
Universitätsspital Zürich, Dermatologische Klinik
City
Zürich
ZIP/Postal Code
8058
Country
Switzerland
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
We'll reach out to this number within 24 hrs